Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Novavax NVAX shares soared 11.4% in the last trading session to close at $6.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

The decision had been expected by April 1, but the agency now says it needs more information before moving forward.

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have received an average recommendation of “Hold” from the seven ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...